



Radiotherapeutics CDMO (Spin-off of  **Centre for Probe Development and Commercialization**)

Introducing AtomVie Global Radiopharma Inc.
Hamilton Health Innovation Check-up
August 29th, 2022

• Empowering Next Generation Radiotherapeutics •



• EMPOWERING NEXT GENERATION RADIOTHERAPEUTICS •

Our Mission

Transforming lives by revolutionizing healthcare.

Our Vision


AtomVie is a global leader in the radiopharmaceutical industry dedicated to transforming patient's lives by advancing high quality drugs for the diagnosis & treatment of diseases.




Radiopharmaceuticals

Pharmaceuticals that carry a radioactive payload

- Targeted radiotherapy




α , β^- emitters
(e.g. ^{225}Ac , ^{131}I , ^{177}Lu)



THERAPEUTICS


β^+ -positron, γ emitters
(e.g. ^{18}F , ^{68}Ga , $^{99\text{m}}\text{Tc}$)



DIAGNOSTICS



A day in a patient's life



Just in time manufacturing

Right first time approach

A **positive** impact on the patient



AtomVie's Origin – Centre for Probe Development & Commercialization (CPDC)



Founded in
2008



Over 110
Employees



Not-for-Profit
CECR



Over \$49M
Grant
Funding



2 Locations in
Canada



High Level of
Technical
Expertise



Health Canada
& FDA
Compliant



Canadian &
International
Client Base



Supply for
45 Clinical
Trials



Global Supply
to 15
Countries



Impacted the
Lives of Over
90,000
Patients



Creation of 4
Companies

CPDC Outreach - Company Creation



Biotech spun-out based on CPDC's R&D
Raised \$363M



Joint venture UHN-CPDC
R&D and clinical trial support



Centre for **Probe Development**
and **Commercialization**




Joint venture BCCA, TRIUMF, Lawson & CPDC
Solid target technology; Raised \$23M USD



**For Profit Contract Development and
Manufacturing Organization**
**GMP Manufacturing and Global Distribution of
Radiotherapeutics**




Expertise Transfer to AtomVie





AtomVie Services Throughout Drug Development






Purpose-Built Facility

Highlights

- 14 clinical and commercial cleanrooms
- QC/Micro lab areas
- Material storage
- Decay room
- Packaging area
- Shipping area



Launch Timeline



Avego invests at least \$40M into AtomVie



Resources Blog Journalists Webcasts Data Privacy Français my CNW Client Login Sign Up Send a Release

CISION News Products Contact Search


News in Focus Business Science & Tech Lifestyle & Health Policy & Public Interest People & Culture Advanced Search

AtomVie Global Radiopharma Inc. Announces its Spinout and Series A Financing with Avego


NEWS PROVIDED BY
[AtomVie Global Radiopharma Inc. →](#)
Aug 24, 2022, 09:00 ET

SHARE THIS ARTICLE

[f](#) [t](#) [in](#) [@](#) [✉](#) [v](#)




AtomVie Global Radiopharma Inc. (CNW Group/AtomVie Global Radiopharma Inc.)



Avego Management, LLC (CNW Group/AtomVie Global Radiopharma Inc.)



The Market for Radiotherapeutics



Targeted radiotherapy: The targeting molecule seeks out the tumors selectively where the isotope delivers lethal doses of radiation

Recent drug approvals include Novartis' Lutathera®

- \$475M USD of sales in 2021

Pluvicto™ (PSMA-617, Lu-177-PSMA targeting therapeutic)

- Endocyte bought the rights from ABX for \$12M (Oct. 2017)
- Novartis bought Endocyte for \$2.1B (Oct. 2018)
 - Global market for prostate cancer treatments estimated at \$11B by 2024 (Novartis)



Global radiopharmaceutical market is expected to exceed over \$10B by 2026 & CDMO >\$5B by 2030

- Industry Research (April, 2021)

Growing pipeline of radiotherapeutics to reach market in the coming years



AtomVie Global Radiopharma offers **clinical & commercial radiopharmaceutical manufacturing** services paired with remarkable connections to **global partners**. AtomVie's unique standing in the radiopharmaceutical industry due to **CPDC's history and contributions** to the global market, prove its **agility** and ability to provide outstanding **Ontario-based** solutions to your needs.



AtomVie
Global Radiopharma

- Empowering Next Generation Radiotherapeutics ●

Contact:

Bruno Paquin, PhD
Chief Executive Officer
bruno.paquin@atomvie.com

Ghadeer Shubassi, PhD
Associate Director, Business Development
ghadeer.shubassi@atomvie.com



AtomVie
Global Radiopharma

- Empowering Next Generation Radiotherapeutics •

Follow us:

www.atomvie.com

<https://www.linkedin.com/company/atomvie/>